AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
AstraZeneca is conducting a Phase III clinical study titled ‘A Phase III, Randomised, Open-label, Sponsor-blinded, Multicentre Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma.’ The study aims to evaluate the efficacy and safety of rilvegostomig combined with bevacizumab, with or without tremelimumab, compared to atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma (HCC).
The study tests three interventions: a combination of rilvegostomig, bevacizumab, and tremelimumab; rilvegostomig and bevacizumab; and atezolizumab with bevacizumab. These drugs are administered as intravenous therapies, targeting advanced HCC in patients unsuitable for curative or locoregional treatments.
This interventional study follows a randomized, parallel assignment model with single masking for outcomes assessors. Its primary purpose is treatment, focusing on the safety and efficacy of the drug combinations.
The study began on May 6, 2025, with its primary completion date yet to be determined. The last update was submitted on July 1, 2025. These dates are crucial as they mark the study’s progress and potential timelines for results.
The update on this study could influence AstraZeneca’s stock performance and investor sentiment, as positive outcomes may enhance the company’s competitive position in the oncology market. Investors should watch for developments, as successful results could impact the broader pharmaceutical landscape.
The study is currently recruiting, and further details are available on the ClinicalTrials portal.